Sign in →

Test Code C125 Cancer Antigen 125

Specimen Type



Mint green top with gel separator

Preferred Volume

3.5 mL

UCMC Collection Instructions

Indicate if patient is receiving HAMA therapy.
Order once per admit. If serial monitoring needed, Q daily.


Monday – Friday 7:00 a.m. – 6:00 p.m.

Turnaround Time

24 – 72 hrs

STAT Availability

Not Available

Test Usage

Immunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum and plasma. These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential). The Elecsys CA 125 II assay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first-line therapy and would be considered for second-look procedures. The Elecsys CA 125 II assay is further indicated for serial measurement of CA 125 to aid in the management of cancer patients.

Test Methodology

Roche Elecsys CA 125 II, Electrochemiluminescence Immunoassay (ECL)

Additional Information

The measured CA 125 value of a patient’s sample can vary depending on the testing procedure used. The laboratory finding must therefore always contain a statement on the CA 125 assay method used. CA 125 values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations.

CPT Code


Test Includes

CA 125 determination

Critical Results


Reference Range

<35 U/mL

Coverage Information

CMS has established a national coverage policy (NCD) for Medicare for this test as of November 25, 2002. Please document medical necessity. For more details click this link:



Minimum Volume

2 mL

Fee Code



CA 125